In addition, overexpression of cell-line-specific or so-called “cancer/testis” antigens in melanoma, such as the differentiation antigens gp100, Melan-A or the highly immunogenic MART/MAGE antigens, were among the first cancer antigens to be identified and classified, thus allowing researchers to develop TAA-directed immunotherapies in melanoma [12,13,14]. This evidence concerns the gene MLANA and cancer.